. 2022 Oct 13;27(20):6848. doi: 10.3390/molecules27206848

Table 2.

Photosensitizers in ongoing and/or approved clinical trials for PDT for cancer.

Photosensitizer (s)	PS Class	Cancer Type (s)	PS-PDT Effective Concentrations	Ref.
Talaporfin, mono-L-aspartyl chlorin e6, NPe6, LS11 (Laserphyrin)	chlorin(e6) derivative	bile duct carcinoma	40 mg.m⁻² combined with 100 J.cm⁻² light dose (664 nm, 4–6 h).	[75]
Talaporfin, mono-L-aspartyl chlorin e6, NPe6, LS11 (Laserphyrin)	chlorin(e6) derivative	bile duct carcinoma	40 mg.m⁻² combined with 100 J.cm⁻² light dose (664 nm, 6 h).	[76]
Disulfonated tetraphenyl chlorin (TPCS2a)	chlorin	Solid tumor	0.25 mg.kg⁻¹, fluence rate of 100 mW.cm⁻², 60 J.cm⁻² light dose (652 nm, 4–6 h).	[77]
Radachlorin	chlorin derivative	obstructive advanced non-small-cell lung cancer	1 mg.kg⁻¹ combined with 200 J.cm⁻² light dose (662 nm, 11 min 6 s).	[78]
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH)	chlorin derivative	laryngeal cancer	4 mg.kg⁻¹ at fluence rate of 100 mW.cm⁻² combined with below 100 J.cm⁻² light dose (665 nm).	[79]
Redaporfin, LUZ11 or F-2BMet, 5,10,15,20-tetrakis(2,6-difluoro-3-N-methylsulfamoylphenyl)-bacteriochlorin	bacteriochlorin derivative	head and neck squamous carcinom	0.75 mg.kg⁻¹combined with 50 J.cm⁻² light dose (749 nm).	[80]
Silicon (IV) phthalocyanine (SiPC)	Phthalocyanines Derivatives	non-melanoma skin cancer	0.1 mg.mL⁻¹ combined with 100–150 mJ.cm⁻¹ light dose.	[81]